ArticleAnnals of surgical oncology2026
Assessing Graded Histological Regression as Basis for Treatment Modification after Neoadjuvant Therapy in LAGC: An Exploratory Phase II Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Refining CT Heterogeneity Scoring to Improve Clear Cell Renal Cell Carcinoma Diagnosis in Small Renal Masses.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundWhether to change adjuvant regimen after ineffective neoadjuvant chemotherapy in locally advanced gastric cancer (LAGC) remains unclear. We conducted an exploratory study on whether graded histologic regression (GHR) < 50% was a potential indicator for regimen modification. PATIENTS AND
methodsThe study was a prospective, single-center, open-label, randomized, phase II trial. Patients were randomly assigned to group A (paclitaxel-modified regimen) and group B (original regimen) for adjuvant chemotherapy. The primary endpoint was disease-free survival (DFS), with secondary endpoints of overall survival (OS) and safety.
resultsBetween May 2017 and August 2025, 58 patients with postoperative GHR < 50% were enrolled and randomly allocated to group A (n = 28) or group B (n = 30). After a median of 19.3 months follow-up, group A had longer median DFS (25.2 months versus 11.4 months) (hazard ratio [HR] 0.4711, 95% confidence interval [CI] 0.2501-0.8874; P = 0.020) and median OS (32.0 months versus 18.0 months) (HR 0.5088, 95% CI 0.2667-0.9708; P = 0.040) than group B. Regimen modification was identified as independent prognostic factor for DFS and OS. In subgroup analysis, compared with ypN0-2, patients with ypN3 stage (P = 0.047) were more likely to experience OS benefits by regimen modification. Patients with ypTNM III stage (P = 0.046) had more DFS benefits from regimen alteration than ypTNM I-II. Regarding adverse events, except higher nausea incidence, chemotherapy change did not significantly increase other adverse reactions.
conclusionsGHR < 50% may indicate the need to adjust adjuvant chemotherapy regimen in LAGC. A larger study is needed to validate its final survival impact.
Indexed as
Identifiers
42563121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.